Work

Oral HIF-2α inhibitor belzutifan for ocular von Hippel-Lindau (VHL) disease

Year: 2021

Type: article

Source: Investigative Ophthalmology & Visual Science

Authors: Henry E. Wiley, Hanna R. Coleman, Eric Jonasch, Ramaprasad Srinivasan, Frede Donskov, A. Kruse, Jodi K. Maranchie, Jay Chhablani, Tobias Else, Hakan Demirci, Benjamin L. Maughan, M. Elizabeth Hartnett, Rodolfo F. Perini, Eric K. Park, Emily Y. Chew

Institutions: National Eye Institute, The University of Texas MD Anderson Cancer Center, National Cancer Institute, Aarhus University Hospital, Aalborg University Hospital, North Denmark Region, University of Pittsburgh, University of Michigan, University of Utah, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Ocular Oncology and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,850

OpenAlex ID: W3193930616

FWCI: 1.347

Cites:

Cited by: 6

Related to: 10